Abstract:
PURPOSE:Methotrexate is an anti-inflammatory drug that has been shown to have anti-ischemic effects. Our aim was to evaluate if methotrexate could reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI). METHODS:We randomly assigned patients with STEMI to receive either methotrexate or placebo. Primary outcome was infarct size determined by calculating the area under the curve (AUC) for creatine kinase (CK) release. Secondary outcomes were AUC of CK MB (CK-MB) and AUC of troponin I; peak CK, peak CK-MB, and troponin I; B-type natriuretic peptide (BNP) level, high-sensitivity C-reactive protein (hsCRP) result, and erythrocyte sedimentation rate (ESR); left ventricular ejection fraction (LVEF); thrombolysis in myocardial infarction (TIMI) frame count; Killip score; mortality and reinfarction incidence; and incidence of adverse reactions. RESULTS:We included 84 patients. Median AUC of CK was 78 861.0 in the methotrexate group and 68 088.0 in the placebo group ( P = .10). Patients given methotrexate and placebo exhibited, respectively, median AUC for CK-MB of 9803.4 and 8037.0 ( P = .42); median AUC for troponin of 3691.1 and 2132.6 ( P = .09); peak CK of 2806.0 and 2147.0 ( P = .05); peak CK-MB of 516.0 and 462.3 ( P = .25); and peak troponin of 121.0 and 85.1 ( P = .06). At 3 months, LVEF was lower in patients who received methotrexate (49.0% ± 14.1%) than in patients given placebo (56.4% ± 10.0%; P = .01). There were no differences in hsCRP, ESR, BNP, Killip scores, TIMI frame count, reinfarction, and mortality rates. There was a higher median serum glutamic-pyruvic transaminase levels in the methotrexate group. CONCLUSION:Methotrexate did not reduce infarction size and worsened LVEF at 3 months ( Clinicaltrials.gov identifier NCT01741558).
journal_name
J Cardiovasc Pharmacol Therjournal_title
Journal of cardiovascular pharmacology and therapeuticsauthors
Moreira DM,Lueneberg ME,da Silva RL,Fattah T,Gottschall CAMdoi
10.1177/1074248417699884subject
Has Abstractpub_date
2017-11-01 00:00:00pages
538-545issue
6eissn
1074-2484issn
1940-4034journal_volume
22pub_type
杂志文章,随机对照试验abstract:BACKGROUND:Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established. This article evaluates an antiarrhythmic action during sympathetic stimulation in the intact anesthetized dog with and without ischemia. METHODS AND RESULT...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1053/XV.2000.5492
更新日期:2000-04-01 00:00:00
abstract::BACKGROUND: The effects of sotalol on the 24-hour profile of the QT interval relative to that of the heart rate (HR) may be helpful in determining the time course of the drug's action in controlling cardiac arhythmias. This has not been previously determined. Thus, the objective of the current study was to evaluate th...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/107424849900400104
更新日期:1999-01-01 00:00:00
abstract:OBJECTIVE:To describe major events at follow up in octogenarian patients with atrial fibrillation (AF) according to anticoagulant treatment: direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs). METHODS:A total of 578 anticoagulated patients aged ≥80 years with AF were included in a prospective, obse...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,多中心研究
doi:10.1177/1074248420916316
更新日期:2020-07-01 00:00:00
abstract:INTRODUCTION:Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased s...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248418772814
更新日期:2018-09-01 00:00:00
abstract::Data obtained in both preclinical models and humans have revealed that the favorable cardiac consequences of ischemic conditioning extend beyond a direct effect on the cardiomyocyte. In the current review, we summarize our as-yet limited understanding of the complex relationships between ischemic conditioning, platele...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/1074248417724871
更新日期:2017-09-01 00:00:00
abstract::Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/1074248418784288
更新日期:2019-01-01 00:00:00
abstract::BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/107424849900400206
更新日期:1999-04-01 00:00:00
abstract:OBJECTIVE:To investigate the effect of a pharmacist care program on cardiovascular risks in type 2 diabetic patients. METHODS:A 9-month, prospective, randomized, controlled study was conducted in a public hospital in Hong Kong. Patients in the intervention group had regular drug-counseling sessions with pharmacists in...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,随机对照试验
doi:10.1177/1074248410396216
更新日期:2012-03-01 00:00:00
abstract::Atrial fibrillation has recently come into clinical and research focus. In particular, ventricular rate control has been carefully compared with atrial rhythm control. Additionally, the recent discovery of atrial stunning has initiated clinical and research interest in atrial remodeling. Atrial fibrillation is more li...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/107424840300800105
更新日期:2003-06-01 00:00:00
abstract::α-Lipoic acid (LA) has been shown to offer protection against ischemia-reperfusion injury (IRI) in multiple organ systems. N-[(R)-1,2-dithiolane-3-pentanoyl]-L-glutamyl-L-alanine (CMX-2043), a novel analogue of LA, was studied as part of a preclinical development program intended to identify safe and efficacious drug ...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248416640118
更新日期:2016-11-01 00:00:00
abstract:PURPOSE:It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mec...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248410380208
更新日期:2011-03-01 00:00:00
abstract::Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of beta 1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chron...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248407312629
更新日期:2008-03-01 00:00:00
abstract::Ventricular remodeling is a compensatory response that comprises the processes of apoptosis, muscle cell hypertrophy, and rearrangement of the extracellular matrix fibers connecting the muscles. These processes are associated with transformation of endothelium and/or fibroblasts to myofibroblasts. Neutral matrix metal...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/107424840200700407
更新日期:2002-10-01 00:00:00
abstract::Myocardial ischemic injury and cardioprotection are characterized by a cascade of molecular changes, which includes gene expression, protein expression, protein localization, interactions, and posttranslational modifications (PTMs). A systems biology approach allows the study of these genes and proteins on a large sca...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/1074248411415855
更新日期:2011-09-01 00:00:00
abstract::Acute medical illnesses are associated with a prolonged elevation in inflammatory markers that predisposes patients to thrombosis beyond the duration of their hospital stay. In parallel, both observational and randomized data have demonstrated a rate of postdischarge venous thromboembolic events that often exceeds tha...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/1074248415601894
更新日期:2016-05-01 00:00:00
abstract:BACKGROUND:CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A(1)-adenosine receptor agonist with potential potent antiarrhythmic effects in tachycardias involving the atrioventricular (AV) node. This study, the first in humans, was designed to determine the effects of CVT-510 on AV nodal condu...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,多中心研究
doi:10.1177/107424840100600304
更新日期:2001-07-01 00:00:00
abstract:INTRODUCTION:Recent evidence suggests that transcriptional reprogramming is involved in the pathogenesis of cardiac remodeling (cardiomyocyte hypertrophy and fibrosis) and the development of heart failure. 5-Azacytidine (5aza), an inhibitor of DNA methylation approved for hematological malignancies, has previously demo...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248420979235
更新日期:2020-12-02 00:00:00
abstract::Cardiovascular diseases are one of the most common causes of death in humans and are responsible for billions of dollars in health care expenditures. As the molecular basis of cardiac diseases continues to be explored, there remains the hope for identification of more effective therapeutics. MicroRNAs (miRNAs) are rec...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/1074248414552902
更新日期:2015-03-01 00:00:00
abstract:INTRODUCTION:Angiotensin converting enzyme inhibitors (ACEIs) are widely prescribed medications. A recent British study reported a 14% increased risk of lung cancer with ACEI versus angiotensin receptor blocker (ARB) prescriptions, and risk increased with longer use. We sought to validate this observation. METHODS:We ...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248420987054
更新日期:2021-01-29 00:00:00
abstract:BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248415575967
更新日期:2015-09-01 00:00:00
abstract::Ischemia-reperfusion injury is a composite of the injury sustained during a period of reduced or absent blood flow to a tissue or organ and the additional insult sustained on reperfusion, which limits the amount of tissue that can be salvaged. Ischemia-reperfusion injury is the predominant insult during kidney transpl...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/1074248417702893
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND/AIM:In addition to its cholesterol-lowering effect, atorvastatin (ATV) has been thought to have multiple cardiovascular benefits, including anti-inflammatory and anti-apoptotic properties. The present study was undertaken to determine whether ATV pretreatment could attenuate myocardial apoptosis and inflamma...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248416662348
更新日期:2017-03-01 00:00:00
abstract:BACKGROUND:The administration of aspirin is traditionally discontinued prior to coronary artery bypass grafting (CABG), given a potential risk of excessive postoperative bleeding. Few studies have previously suggested the benefits of continuing aspirin until the time of surgery. The primary aim of this review is to eva...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,meta分析,评审
doi:10.1177/1074248413509026
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor. Statins are reported to increase 25(OH)VitD concentration. Animal studies suggest that ezetimibe is a moderate inhibitor of intestinal 25(OH)VitD absorption, but its effect in humans i...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,随机对照试验
doi:10.1177/1074248412470513
更新日期:2013-05-01 00:00:00
abstract::Homing of cardiac myosin-specific CD4-positive T cells into the myocardium is the initial pathologic event of experimental autoimmune myocarditis (EAM). Subsequently, various bystander inflammatory cells are recruited into the myocardium crossing vascular endothelial cell walls. Sulfated polysaccharide fucoidan binds ...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248410378751
更新日期:2011-03-01 00:00:00
abstract::The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become appar...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/107424840400900i109
更新日期:2004-03-01 00:00:00
abstract:BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another ther...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/107424840000500103
更新日期:2000-01-01 00:00:00
abstract::Postischemic accumulation of intracellular Na+ promotes calcium overload and contributes to cellular necrosis. Cardioprotection afforded by pharmacologic blockade of the sodium-hydrogen exchanger subtype 1 (NHE1) is thought to be more remarkable than that obtained by ischemic conditioning (IC). The window of protectio...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248418755120
更新日期:2018-05-01 00:00:00
abstract::Beta-Adrenergic blockers have a wide spectrum of action for controlling cardiac arrhythmias that is larger than initially thought. Data from the past several decades indicate that, as an antiarrhythmic class, beta-blockers remain among the very few pharmacologic agents that reduce the incidence of sudden cardiac death...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章,评审
doi:10.1177/10742484050100i402
更新日期:2005-06-01 00:00:00
abstract::The antiarrhythmic potential of postconditioning in in vivo models remains poorly defined. We compared the effects of pre- and postconditioning on ventricular arrhythmogenesis against controls with and without reperfusion. Wistar rats (n = 40, 269 ± 3 g) subjected to ischemia (30 minutes)--reperfusion (24 hours) were ...
journal_title:Journal of cardiovascular pharmacology and therapeutics
pub_type: 杂志文章
doi:10.1177/1074248413482183
更新日期:2013-07-01 00:00:00